EVREN TECHNOLOGIES, INC. APPOINTS RICK GIANCOLA AS PRESIDENT
Giancola Brings 35 Years of Life Sciences Industry Experience to Evren Tech
For Immediate Release - Gainesville, Florida – December 14, 2023 – Evren Technologies, Inc., a leader in developing bioelectronic medical devices and solutions for treating PTSD, is pleased to announce the appointment of Rick Giancola as President. With over 35 years of experience in the life sciences industry, Mr. Giancola brings a wealth of knowledge and a proven track record of business development and strategic growth success to this role. He is passionate about neuromodulation technology and its powerful ability to transform lives.
As Owner and Managing Director of Otomed Consulting, LLC, Mr. Giancola has advised global leaders, emerging companies, venture capital and investment firms in the life sciences space on business development and operational systems of neuromodulation devices, including novel tinnitus treatments, hearing implants and innovative approaches for other neurological disorders.
At Cochlear Americas, his team built the Latin American business, growing revenue by 30% year-over-year and establishing Latin America as a key component of Cochlear’s global strategy. At Cochlear, he was responsible for all regional sales, marketing, clinical, distribution, education and research activities. He then joined Neuromonics, Inc. as CEO (later acquired by SoundVida) and bone conduction hearing pioneer Sophono (acquired by Medtronic).
As Executive Vice President of the Americas/EMEA at Nurotron Biotechnology, Inc., Mr. Giancola drove significant growth by heading all commercial, clinical, research, regulatory, education and training activities for the Americas, Europe, the Middle East and Africa. His strategic initiatives resulted in a fivefold increase in sales in Latin America and EMEA in these diverse global markets.
"We welcome Rick as Evren Technologies, Inc.'s President and Global Executive Leader. His extensive experience, leadership capabilities and strategic vision will undoubtedly elevate our company to new heights," said Weaver Gaines, Co-Founder and CEO of Evren Technologies, Inc.
Mr. Giancola holds an MBA from Syracuse University and a BA from Hobart College. His commitment to professional and community involvement is evident through his roles on various boards and committees.
About Evren Technologies
Evren Technologies. is an innovator in neuromodulation (bioelectronic) medical devices. They are transforming the treatment of PTSD, Acute Stress Reactions, Acute Stress Disorder, and adjustment disorder by delivering noninvasive Vagal Nerve Stimulation VNS to the vagus nerve - which controls the parasympathetic (“fight or flight") branch of the autonomic nervous system. PTSD, stress, anxiety, adjustment disorder, fear, tinnitus and depression are the unfortunate result of extreme stress incidents such as combat, traumatic brain injury, assault and sexual trauma. PTSD and related events comprise over 234 billion in healthcare costs annually. In 2023, Evren launched the Phoenix® CR, a research device that administers transcutaneous auricular VNS (taVNS) safely and effectively in laboratory, clinical, and unsupervised home settings for VNS research under IRB control. The FDA awarded the Phoenix its Breakthrough Device Designation. Evren is conducting clinical trials and seeking De Novo classification from the FDA for the Phoenix. For further information, please visit evrenvns.com.
CONTACT:
Josh Kelly, Director of Operations
Evren Technologies, Inc.
904.517.2432